Porebski, Benjamin T. http://orcid.org/0000-0003-1398-0442
Balmforth, Matthew http://orcid.org/0000-0003-2651-9428
Browne, Gareth
Riley, Aidan
Jamali, Kiarash http://orcid.org/0009-0008-4805-9518
Fürst, Maximillian J. L. J. http://orcid.org/0000-0001-7720-9214
Velic, Mirko
Buchanan, Andrew http://orcid.org/0000-0002-5191-7682
Minter, Ralph http://orcid.org/0000-0001-5571-3102
Vaughan, Tristan
Holliger, Philipp http://orcid.org/0000-0002-3440-9854
Funding for this research was provided by:
RCUK | Medical Research Council (U105178804)
MRC-AstraZeneca Blue Sky Grant BSF24
RCUK | MRC | Medical Research Foundation
Astra Zeneca
European Molecular Biology Organization (ALTF 648-202)
Article History
Received: 5 December 2022
Accepted: 23 August 2023
First Online: 9 October 2023
Competing interests
: The MRC-LMB has filed a patent application on the methodologies described in this article, with B.T.P. and P.H. named as inventors. A.B., G.B. and A.R. are current employees of AstraZeneca. M.B. is a current employee of UCB Pharma. R.M. is a current employee of Alchemab Therapeutics. The other authors declare no competing interests.